Literature DB >> 9371428

Enhancement of the in vivo circulation lifetime of L-alpha-distearoylphosphatidylcholine liposomes: importance of liposomal aggregation versus complement opsonization.

P L Ahl1, S K Bhatia, P Meers, P Roberts, R Stevens, R Dause, W R Perkins, A S Janoff.   

Abstract

Incorporation of N-(omega-carboxy)acylamido-phosphatidylethanolamines (-PEs) into large unilamellar vesicles (LUVs) of L-alpha-distearoylphosphatidylcholine (DSPC) was found to dramatically increase the in vivo liposomal circulation lifetime in rats, reaching a maximal effect at 10 mol.% of the total phospholipid. Neither pure DSPC liposomes nor those with the longest circulating derivative, N-glutaryl-dipalmitoylphosphatidylethanolamine (-DPPE), were found to significantly bind complement from serum. Therefore, the relatively short circulation time of pure DSPC liposomes did not appear to be related to greater complement opsonization leading to uptake by the reticuloendothelial system. However, N-(omega-carboxy)acylamido-PEs were particularly efficient inhibitors of a limited aggregation detected for pure DSPC liposomes. The aggregation tendency of DSPC liposomes incorporating various structural analogs of N-glutaryl-DPPE correlated inversely with the circulation lifetimes. Therefore, it is concluded that such PE derivatives enhance the circulation time by preventing liposomal aggregation and avoiding a poorly understood mechanism of clearance that is dependent on size but is independent of complement opsonization. At high concentrations of N-glutaryl-DPPE (above 10 mol.%), the liposomes exhibited strong complement opsonization and were cleared from circulation rapidly, as were other highly negatively charged liposomes. These data demonstrate that both the lack of opsonization and the lack of a tendency to aggregate are required for long circulation. Liposomal disaggregation via N-(omega-carboxy)acylamido-PEs yields a new class of large unilamellar DSPC liposomes with circulation lifetimes that are comparable to those of sterically stabilized liposomes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371428     DOI: 10.1016/s0005-2736(97)00129-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

1.  Post-modification of preformed liposomes with novel non-phospholipid poly(ethylene glycol)-conjugated hexadecylcarbamoylmethyl hexadecanoic acid for enhanced circulation persistence in vivo.

Authors:  Okhil K Nag; Vivek R Yadav; Andria Hedrick; Vibhudutta Awasthi
Journal:  Int J Pharm       Date:  2013-02-16       Impact factor: 5.875

Review 2.  Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs.

Authors:  Sean M Geary; Aliasger K Salem
Journal:  Crit Rev Oncog       Date:  2014

3.  Targeting of Cancer Cells Using Quantum Dot-Polypeptide Hybrid Assemblies that Function as Molecular Imaging Agents and Carrier Systems.

Authors:  Bayu Atmaja; Bertrand H Lui; Yuhua Hu; Stayce E Beck; Curtis W Frank; Jennifer R Cochran
Journal:  Adv Funct Mater       Date:  2010-12-08       Impact factor: 18.808

Review 4.  Liposomes in tissue engineering and regenerative medicine.

Authors:  Nelson Monteiro; Albino Martins; Rui L Reis; Nuno M Neves
Journal:  J R Soc Interface       Date:  2014-12-06       Impact factor: 4.118

5.  Insights into accelerated liposomal release of topotecan in plasma monitored by a non-invasive fluorescence spectroscopic method.

Authors:  Kyle D Fugit; Amar Jyoti; Meenakshi Upreti; Bradley D Anderson
Journal:  J Control Release       Date:  2014-10-25       Impact factor: 9.776

6.  Revealing Dynamics of Accumulation of Systemically Injected Liposomes in the Skin by Intravital Microscopy.

Authors:  James I Griffin; Guankui Wang; Weston J Smith; Vivian P Vu; Robert Scheinman; Dominik Stitch; Radu Moldovan; Seyed Moein Moghimi; Dmitri Simberg
Journal:  ACS Nano       Date:  2017-10-18       Impact factor: 15.881

Review 7.  Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders.

Authors:  Caroline Vissers; Guo-Li Ming; Hongjun Song
Journal:  Adv Drug Deliv Rev       Date:  2019-02-21       Impact factor: 15.470

Review 8.  Innate and adaptive immune responses toward nanomedicines.

Authors:  Iara Maíra de Oliveira Viana; Sabrina Roussel; Joan Defrêne; Eliana Martins Lima; Frédéric Barabé; Nicolas Bertrand
Journal:  Acta Pharm Sin B       Date:  2021-03-13       Impact factor: 11.413

9.  Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.

Authors:  Anja C Mortensen; Diana Spiegelberg; Anna-Karin Haylock; Hans Lundqvist; Marika Nestor
Journal:  Int J Oncol       Date:  2018-04-11       Impact factor: 5.650

10.  In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study.

Authors:  Anna-Karin Haylock; Diana Spiegelberg; Johan Nilvebrant; Karl Sandström; Marika Nestor
Journal:  EJNMMI Res       Date:  2014-03-06       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.